title: In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis.
abstract: Angiopoietin-1 (Ang-1) and its naturally occurring antagonist angiopoietin-2 (Ang-2) are novel ligands that regulate tyrosine phosphorylation of the Tie2/Tek receptor on endothelial cells. Proper regulation of Tie2/Tek is absolutely required for normal vascular development, seemingly by regulating vascular remodeling and endothelial cell interactions with supporting pericytes/smooth muscle cells. We investigated the expression of Ang-1 and Ang-2 in human astrocytomas by in situ hybridization and compared them to the distribution of pericytes/smooth muscle cells by immunohistochemistry for alpha-smooth muscle actin (SMA). Ang-1 mRNA was localized in tumor cells and Ang-2 mRNA was detected in endothelial cells of hyperplastic and nonhyperplastic tumor vessels. Ang-2 was also expressed in partially sclerotic vessels and in vascular channels surrounded by tumor cells in brain adjacent to the tumor. Neither Ang-1 nor Ang-2 was detected in normal brain. Dynamic changes in SMA expression during glioma tumorigenesis appear to progress from fragmentation in early vascular hyperplasia to subsequent reassociation and enhanced expression in later stages of vascular proliferation in hyperplastic complexes in high-grade gliomas. All these vessels displaying dynamic changes in SMA immunoreactivity also expressed Ang-2 mRNA. Moreover, SMA immunoreactive intratumoral vascular channels lacking morphological evidence of hyperplasia also showed upregulation of Ang-2. These results suggest that angiopoietins are involved in the early stage of vascular activation and in advanced angiogenesis, and they identify Ang-2 as an early marker of glioma-induced neovascularization. The association between Ang-2 expression and alterations in SMA immunoreactivity suggests a role for Ang-2 in tumor-associated activation of pericytes/smooth muscle cells.
authors.affiliation: Division of Neuropathology, New York University Medical Center, New York, New York, 10016, USA.
authors.forename: D
authors.initials: D
authors.lastname: Zagzag
authors.forename: A
authors.initials: A
authors.lastname: Hooper
authors.forename: D R
authors.initials: DR
authors.lastname: Friedlander
authors.forename: W
authors.initials: W
authors.lastname: Chan
authors.forename: J
authors.initials: J
authors.lastname: Holash
authors.forename: S J
authors.initials: SJ
authors.lastname: Wiegand
authors.forename: G D
authors.initials: GD
authors.lastname: Yancopoulos
authors.forename: M
authors.initials: M
authors.lastname: Grumet
mesh_terms: D042683:Angiopoietin-1; D042702:Angiopoietin-2; D001254:Astrocytoma / Q000098:blood supply* / Q000235:genetics*; D015415:Biomarkers; D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000098:blood supply* / Q000235:genetics*; D004791:Enzyme Inhibitors; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000098:blood supply / Q000235:genetics; D006801:Humans; D017403:In Situ Hybridization; D008562:Membrane Glycoproteins / Q000235:genetics; D009389:Neovascularization, Pathologic; D011506:Proteins / Q000235:genetics*; D012016:Reference Values; D014158:Transcription, Genetic
chemical_list: C467630:ANGPT1 protein, human; D042683:Angiopoietin-1; D042702:Angiopoietin-2; D015415:Biomarkers; D004791:Enzyme Inhibitors; D008562:Membrane Glycoproteins; D011506:Proteins